Corcept Therapeutics | CORT - Interest Expense On Debt


Corcept Therapeutics reported $814.88M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alaunos Therapeutics USD 1.07M 215K Jun/2023
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Ardelyx USD 5.6M 160K Mar/2026
Aurora Cannabis CAD 230K 1.88M Mar/2026
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Corcept Therapeutics USD 814.88M 809.46M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
J&J USD 43M 25M Mar/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Merck USD 479M 67M Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 343M 39M Mar/2026
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.7M 193K Mar/2026
Pfizer USD 671M 40M Mar/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
TG Therapeutics USD 7.67M 1.13M Mar/2026